Sanjivani Paranteral Ltd Q1 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/7g2islsnxo56iuholfshsva0.pdf

Key Takeaways


Margin Shock: Freight, Mix, and the Rebound Bet

Srivardhan Khemka: "the freight costs have gone up in certain segments where we operate around four to five times of the regular rates due to which the EBITDA margins have dropped."

The Joint Ventures: HAL and Prague


Product Strategy: Injectables First, Nutraceuticals Second

Srivardhan Khemka: "Our primary focus remains injectables. And with the Hindustan Antibiotics plant coming in, our focus on injectables and the numbers will also show similarly."

The PPP Model: A Primitive but Real Option

Ashwani Khemka: "These are internal things. The government doesn't disclose unless they have published out the tenders. And those tenders are a public property. Everybody can go and visit the same. So, this is very primitive, it's a standard discussion only. And certain means cannot be revealed, okay, because there are many players also."

Capital Allocation and the Balance Sheet


Guidance & Commitments

CommitmentSpecificsTimeline
HAL JV commercial launchFirst commercial batch in marketOctober 15, 2024 onwards
Prague JV full-speed operationsTeething issues resolved, full capacityEnd of August or September 2024
Base business growthApproximately 25% year-on-yearFY25
Margin recovery trajectoryMargins improve quarter-on-quarter from current low levelsOngoing from Q2 FY25
HAL revenue contributionOne quarter of revenue in FY25; full year in FY26FY25 / FY26
Import substitute IV product development9–12 month development timeline, R&D starts post-OctoberFY26
Maintenance CAPEX₹10–12 crores spread over current and next financial yearFY25–FY26
Export/domestic mix post-HALConsolidated mix moves to approximately 50:50Post-HAL consolidation

Key Metrics

MetricQ1 FY25
Revenue₹16.44 cr, +31% YoY
EBITDA margin14.7%, compared to 16.5% in Q1 FY24
Net profit₹1.71 cr, +11% YoY
PAT margin10.4%, compared to 12.3% in Q1 FY24
Gross margin38%, compared to ~48% in Q1 FY24 and ~60% in Q4 FY24
Injectables revenue growth+4.6% YoY
Oral solids revenue growth+116.6% YoY
Nutraceuticals revenue growth+61.3% YoY
Domestic revenue share12.8% of total revenue
Export revenue share87.2% of total revenue
CDMO revenue share10% to 11% of base business revenue
Capacity utilization, injectables65% to 68%
Capacity utilization, oral solids35% to 40%
Base business growth guidance~25% YoY for FY25
HAL JV revenue expectationOne quarter of revenue in FY25, full year in FY26
Maintenance CAPEX guidance₹10 cr to ₹12 cr, spread across multiple periods
Net debtZero on books